Bank of America Corp DE Has $579.59 Million Position in Sanofi (NASDAQ:SNY)

Bank of America Corp DE raised its holdings in Sanofi (NASDAQ:SNY - Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,017,140 shares of the company's stock after purchasing an additional 441,637 shares during the period. Bank of America Corp DE owned approximately 0.47% of Sanofi worth $579,587,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. increased its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after buying an additional 543 shares during the period. Bessemer Group Inc. increased its position in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the period. Lee Danner & Bass Inc. bought a new position in Sanofi during the 4th quarter worth approximately $31,000. Finally, Sierra Ocean LLC bought a new stake in shares of Sanofi in the 4th quarter valued at $44,000. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research note on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. The Goldman Sachs Group assumed coverage on Sanofi in a research report on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Finally, Sanford C. Bernstein raised shares of Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $63.33.

Sanofi Price Performance

Sanofi stock opened at $54.59 on Tuesday. The firm has a market capitalization of $137.91 billion, a P/E ratio of 21.92, a PEG ratio of 1.01 and a beta of 0.55. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The business has a fifty day moving average price of $54.53 and a 200-day moving average price of $52.03.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The business had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same quarter in the previous year, the firm earned $1.78 EPS. The company's quarterly revenue was down 11.0% compared to the same quarter last year. As a group, equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a $2.0369 dividend. This represents a yield of 3.1%. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. Sanofi's dividend payout ratio (DPR) is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.